生物主动脉瓣置换术后早期抗凝是否必要？

Is early anticoagulation necessary after biological aortic valve replacement?

作者信息

Benzadón Mariano Noel, Thierer Jorge Mario, Trivi Marcelo, Vrancic Mariano, Fieg Sebastian, Piccinini Fernando, Vaccarino Guillermo, Navia Daniel

出版信息

Int J Cardiol. 2008 Aug 29;128(3):422-3. doi: 10.1016/j.ijcard.2007.08.065. Epub 2007 Dec 18.

DOI:10.1016/j.ijcard.2007.08.065

PMID:18068239

Abstract

Early antithrombotic therapy after biological aortic valve replacement (AVR) is controversial. The aim of this study was to determine the rate of thromboembolic events (TE) without anticoagulation treatment during the first 3 months after surgery. Out of 143 consecutive patients who underwent biological AVR from January 1998 to December 2004, 127 patients who did not receive anticoagulation were included (89%). Events during the first 3 months after surgery included: 2 strokes (1.5%), 2 major bleedings (1.5%) and 9 deaths (7%) (none of them due to TE). In conclusion, the management of patients without antithrombotic treatment after biological AVR seems to be safe due to a low rate of TE.

摘要

生物主动脉瓣置换术（AVR）后早期抗血栓治疗存在争议。本研究的目的是确定术后前3个月未进行抗凝治疗时血栓栓塞事件（TE）的发生率。在1998年1月至2004年12月连续接受生物AVR的143例患者中，127例未接受抗凝治疗的患者被纳入研究（89%）。术后前3个月发生的事件包括：2例中风（1.5%）、2例大出血（1.5%）和9例死亡（7%）（均非由TE导致）。总之，生物AVR后未进行抗血栓治疗的患者管理似乎是安全的，因为TE发生率较低。